2H51 Stock Overview A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Ocugen Historical stock prices Current Share Price US$0.35 52 Week High US$0.35 52 Week Low US$0.35 Beta 3.56 1 Month Change 0% 3 Month Change n/a 1 Year Change -65.59% 3 Year Change n/a 5 Year Change n/a Change since IPO -93.48%
Recent News & Updates
Ocugen, Inc. Announces Data and Safety Monitoring Board Reviewed Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 19
Ocugen, Inc. Announces Compelling Preliminary Data for OCU410--Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Nov 20
Ocugen, Inc. Announces Executive Changes Nov 16 Ocugen, Inc. announced that it has received $30 million in funding Nov 08
Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 17
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial Oct 09 See more updates
Ocugen, Inc. Announces Data and Safety Monitoring Board Reviewed Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 19
Ocugen, Inc. Announces Compelling Preliminary Data for OCU410--Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Nov 20
Ocugen, Inc. Announces Executive Changes Nov 16 Ocugen, Inc. announced that it has received $30 million in funding Nov 08
Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 17
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial Oct 09
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Aug 05 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million. Aug 02
Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.
Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 29
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy Jul 25
Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease Jun 21
Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication Jun 20
Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc Jun 05
Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410 Jun 01
Ocugen, Inc., Annual General Meeting, Jun 28, 2024 May 21
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy May 16
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024 Apr 30
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy Apr 20 Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial Apr 10
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy Apr 05
Ocugen Provides Business Update Apr 03 Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer Mar 20
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 Mar 14
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Feb 23
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board Jan 16
Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design Dec 22
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 14
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease Nov 11 Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023
Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials Oct 11
Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board Sep 22
Ocugen, Inc. Announces Executive Changes Sep 21
Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Sep 14
Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023 Aug 19
Ocugen, Inc. announced delayed 10-Q filing Aug 17
Ocugen, Inc. Announces Business Advisory Board Jun 06 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million. May 26
Ocugen, Inc. has completed a Follow-on Equity Offering. May 25
No longer forecast to breakeven Mar 03
Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 16
Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer Feb 02
Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met Jan 10
Forecast to breakeven in 2025 Dec 31
Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis Dec 08
High number of new directors Nov 16
Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 28
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 Oct 13
Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology Sep 15
Ocugen, Inc. Announces Board Changes Sep 02
No longer forecast to breakeven Aug 14
Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022 Jul 30
Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases Jun 22
Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition May 26
Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition May 25
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152) May 24
Forecast breakeven date pushed back to 2023 May 14
Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022 May 03
High number of new and inexperienced directors Apr 27
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial Apr 26
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152) Apr 13
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Apr 03
Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer Mar 07 Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request
Forecast breakeven date pushed back to 2023 Mar 05
Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million. Feb 25 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million. Feb 24
Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N). Jan 28
Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory University Jan 13
Ocugen, Inc. Announces COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Jan 09
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine Dec 31
Ocugen, Inc. announces New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination Dec 16 Shareholder Returns 2H51 BG Biotechs BG Market 7D 0% 0% 0% 1Y -65.6% 0% 0%
See full shareholder returns
Return vs Industry: 2H51 underperformed the BG Biotechs industry which returned -8.1% over the past year.
Return vs Market: 2H51 underperformed the BG Market which returned 11.5% over the past year.
Price Volatility Is 2H51's price volatile compared to industry and market? 2H51 volatility 2H51 Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in BG Market 0% 10% least volatile stocks in BG Market 0%
Stable Share Price: 2H51 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2H51's volatility change over the past year.
About the Company Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market.
Show more Ocugen, Inc. Fundamentals Summary How do Ocugen's earnings and revenue compare to its market cap? 2H51 fundamental statistics Market cap €234.13m Earnings (TTM ) -€69.63m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2H51 income statement (TTM ) Revenue US$0 Cost of Revenue US$47.28m Gross Profit -US$47.28m Other Expenses US$28.24m Earnings -US$75.52m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/28 19:43 End of Day Share Price 2023/12/01 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ocugen, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristen Kluska Cantor Fitzgerald & Co. Daniil Gataulin Chardan Capital Markets, LLC Swayampakula Ramakanth H.C. Wainwright & Co.
Show 3 more analysts 